David R. Ebsworth - Aug 1, 2025 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Director
Signature
/s/ Andrew Fisher, Attorney-in-fact for David R. Ebsworth
Stock symbol
VRNA
Transactions as of
Aug 1, 2025
Transactions value $
-$25,026
Form type
4
Date filed
8/5/2025, 08:21 PM
Previous filing
May 5, 2025
Next filing
Oct 8, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
EBSWORTH DAVID R Director 3 MORE LONDON RIVERSIDE, LONDON, UNITED KINGDOM /s/ Andrew Fisher, Attorney-in-fact for David R. Ebsworth 2025-08-05 0001207107

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Options Exercise $0 +24K +2.8% $0.00 882K Aug 1, 2025 Direct F1, F2
transaction VRNA Ordinary Shares Sale -$25K -1.9K -0.22% $13.14 880K Aug 1, 2025 Direct F1, F3, F4, F5
holding VRNA Ordinary Shares 618K Aug 1, 2025 By Ebsworth GmbH F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRNA Restricted Stock Units Options Exercise $0 -24K -25% $0.00 72K Aug 1, 2025 Ordinary Shares 24K Direct F1, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Excludes 617,600 Ordinary Shares represented by 77,200 ADSs that were transferred from the Reporting Person to a limited liability company of which the Reporting Person is the sole shareholder.
F3 The sale reported in the Form 4 represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the Reporting Person's tax withholding obligation upon the vesting of the restricted stock units ("RSUs").
F4 The price reported represents the sale price of the ADSs divided by eight (8).
F5 Consists of (i) 880,496 Ordinary Shares represented by 110,062 ADSs and (ii) 3 Ordinary Shares.
F6 Consists of 617,600 Ordinary Shares represented by 77,200 ADSs.
F7 Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
F8 The RSUs vest as to 25% of the total shares on each of August 1, 2025, November 1, 2025, February 1, 2026 and May 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney.